ICJ's Decision in Australia v. Japan: Giving up the Spear or Refining the Scientific Design?

The case Whaling in the Antarctic (Australia v. Japan) decided by the International Court of Justice is a landmark that introduces new parameters for measuring the “reasonableness” of scientific research by permit under the International Convention on Whaling. However, aspects of these parameters and how they may be applied in future cases remain uncertain. Because the Court's interpretation of the language “for purposes of scientific research” avoids defining scientific research, the Court's decision provides only a limited degree of clarification for States that intend to operate scientific whaling programs under Article VIII of the Convention. The Court's reasonableness test is unlikely to prevent scientific whaling. States who no longer support the dual object and purpose of the Whaling Convention may want to consider negotiating a new international instrument that would be more protective of whales and their habitat.     

The Duty to Protect Others From Your Patients—Tarasoff Spreads to the Northwest

The California Supreme Court''s Tarasoff decision was the seminal case in the area of the duty to protect third parties from the potential of violence from patients. Tarasoff-related issues have now spread to many jurisdictions in the country. This article will pay particular attention to the cases influencing law in Washington and Oregon and will review the clinical duty to protect others from your patients that existed before Tarasoff, as physicians were taught to work between privilege and civil commitment statutes. The California law designed to limit Tarasoff liability and the reasons why legislators should be willing to support such legislation are discussed.     

How Might the European Union Engage Constructively with China in the South China Sea?

The decision of the International Court of Justice in the Australia/Japan Whaling Case marks an advance in the law of the sea and the obligation on states to cooperate in common ocean resource regimes. The Court found substantially for Australia, prohibiting Japan's long-running program to capture large cetaceans in the Southern Ocean around Antarctica for scientific research. The Court's discussion of the criteria for states to design and implement scientific research whaling programs is assessed, as is the obligation for cooperation in such research and ocean research generally. The result for whaling and for the future work of the International Whaling Commission is considered.     

The men of Nelson's navy: a comparative stable isotope dietary study of late 18th century and early 19th century servicemen from Royal Naval Hospital burial grounds at Plymouth and Gosport, England

The Guizhou snub‐nosed monkey (Rhinopithecus brelichi) is a primate species endemic to the Wuling Mountains in southern China. With a maximum of 800 wild animals, the species is endangered and one of the rarest Chinese primates. To assess the genetic diversity within R. brelichi and to analyze its genetic population structure, we collected fecal samples from the wild R. brelichi population and sequenced the hypervariable region I of the mitochondrial control region from 141 individuals. We compared our data with those from the two other Chinese snub‐nosed species (R. roxellana, R. bieti) and reconstructed their phylogenetic relationships and divergence times. With only five haplotypes and a maximum of 25 polymorphic sites, R. brelichi shows the lowest genetic diversity in terms of haplotype diversity (h), nucleotide diversity (π), and average number of pairwise nucleotide differences (Π). The most recent common ancestor of R. brelichi lived ～0.36 million years ago (Ma), thus more recently than those of R. roxellana (～0.91 Ma) and R. bieti (～1.33 Ma). Phylogenetic analysis and analysis of molecular variance revealed a clear and significant differentiation among the three Chinese snub‐nosed monkey species. Population genetic analyses (Tajima's D, Fu's F_s, and mismatch distribution) suggest a stable population size for R. brelichi. For the other two species, results point in the same direction, but population substructure possibly introduces some ambiguity. Because of the lower genetic variation, the smaller population size and the more restricted distribution, R. brelichi might be more vulnerable to environmental changes or climate oscillations than the other two Chinese snub‐nosed monkey species. Am J Phys Anthropol, 2012. © 2011 Wiley Periodicals, Inc.     

Mother-cub relationships in giant pandas in the Qinling Mountains,China, with comment on rescuing abandoned cubs

Six cases of mother-cub relationships in wild giant pandas (Ailuropoda melanoleuca) were observed in the Qinling Mountains, China. It was found that panda cubs are normally left alone in the den for 4–8 h while mothers forage. The mother's absence during bouts of foraging should be considered when rescuing abandoned cubs in order to avoid adding to the decline of the wild population. © 1994 Wiley-Liss, Inc.     

Genetic variability and population differentiation in captive baird's Tapirs (Tapirus bairdii)

The objectives of this study were to assess the level of genetic variability and population differentiation within captive populations of an endangered large mammal, Baird's tapir (Tapirus bairdii). We genotyped 37 captive animals from North American (NA) and Central American (CA) zoos and conservation ranches using six polymorphic microsatellite loci. Standard indices of genetic variability (allelic richness and diversity, and heterozygosity) were estimated and compared between captive populations, and between captive and wild population samples. In addition, we evaluated levels of population differentiation using Weir and Cockerham's version of Wright's F-statistics. The results indicate that the NA and CA captive populations of Baird's tapirs have retained levels of genetic variability similar to that measured in a wild population. However, inbreeding coefficients estimated from the molecular data indicate that the CA captive population is at increased risk of losing genetic variability due to inbreeding. Despite this, estimated levels of population differentiation indicate limited divergence of the CA captive population from the wild population. Careful management appears to have kept inbreeding coefficients low in the NA captive population; however, population differentiation levels indicate that the NA population has experienced increased divergence from wild populations due to a founder effect and isolation. Based on these results, we conclude that intermittent exchanges of Baird's tapirs between the NA and CA captive populations will benefit both populations by increasing genetic variability and effective population size, while reducing inbreeding and divergence from wild populations. Zoo Biol 23:521–531, 2004. © 2004 Wiley-Liss, Inc.     

Protein requirements of three species of parrots with distinct dietary specializations

Dietary protein deficiency is considered a major obstacle in the evolution of highly specialized nectarivorous and frugivorous birds. Proposed physiological mechanisms that enable such specialists to subsist on low‐protein diets include minimized endogenous protein losses, which contribute to reduced protein requirements. I compared these traits among nectarivorous red lories (Eos bornea), frugivorous Pesquet's parrots (Psittrichas fulgidus), and granivorous budgerigars (Melopsittacus undulatus). My results suggest that, relative to budgerigars, red lories and Pesquet's parrots have low endogenous protein losses and reduced crude protein (CP) requirements. Based on nitrogen balance analyses, diets containing 1.0%, 3.2%, and 8.2% CP (on a dry matter (DM) basis) would meet the minimal protein requirements for maintenance for red lories, Pesquet's parrots, and budgerigars, respectively. Low endogenous protein losses and reduced protein requirements are effective physiological adaptations that allow birds such as red lories and Pesquet's parrots to specialize on low‐protein foods. Zoo Biol 22:163–177, 2003. © 2003 Wiley‐Liss, Inc.     

Review article: Migrants,minorities, and Mosleyites

Kenneth Lunn (ed.), Hosts, Immigrants, and Minorities: Historical Responses to Newcomers in British Society, 1870–1914; Folkestone: Dawson, 1980, 377 pp., £15.00.

Colin Holmes, Antisemitism in British Society, 1876–1939; London: Arnold, 1979, 328 pp., £13.50.

Gisela C. Lebzelter, Political Antisemitism in England, 1918–39; London: Macmillan, in association with St Antony's College, Oxford, 1978, 222 pp., £10.00.

Kenneth Lunn & Richard C. Thurlow (eds), British Fascism: Essays on the Radical Right in Inter‐War Britain; London: Croom Helm, 1980, 234 pp., £12.95.     

Milk intake and development in a newborn captive African elephant (Loxodonta africana)

In August 2003 the San Diego Zoo's Wild Animal Park (WAP) and the Lowry Park Zoo, under the auspices of the AZA's Elephant SSP and a USFWS permit, imported 3.8 African elephants (Loxodonta africana) from the Kingdom of Swaziland. When they were captured, transrectal ultrasound examinations revealed that one nulliparous cow was approximately 10 months pregnant. At the time of their arrival (August 2003), all of the animals were estimated to be approximately 13 years old and were thought to be nulliparous. Based on the ultrasound examination results and the average African elephant gestation period, parturition was predicted to be 20 February 2004. In this report, we provide the first detailed data about nursing activity around the clock and newborn calf development, describe maternal and neonatal nighttime activity budgets, and explore maternal weight changes during suckling and lactation. The newborn calf suckled significantly more at night than during the day, but suckled for only about 2 hr per 24‐hr period. Regression analysis revealed that through the first 3 months of life the calf gained 0.385 kg/day while it suckled on a regular basis. We compare our findings with published information on wild elephants, and conclude that although the growth rate is reduced compared to hand‐reared elephant calves, the suckling patterns are almost identical to those reported for wild calves. Zoo Biol 0:1–7, 2005. © 2005 Wiley‐Liss, Inc.     

Changes in behavior in free‐ranging Lemur catta following release in a natural habitat

The adjustment of captive‐reared and developmentally deprived ringtailed lemurs (Lemur catta) to supported release on St. Catherine's Island, Georgia, was studied over 7 years to examine if these animals developed behavior comparable to wild populations. Initial changes after release included decreased obesity and increased agility as well as foraging for appropriate novel plants. Ranging, daily behavior cycles, and vocalizations developed more slowly over 1–3 years, but eventually the behavior resembled that of wild groups. Group composition and social structure changed through conflict to resemble wild and captive troops in social organization, including the emergence of matrilineal dominance and male emigration. Since behavior eventually resembled that seen in the wild, some resilience of species‐typical wild behavior in captivity is supported. Am. J. Primatol. 47:15–28, 1999. © 1999 Wiley‐Liss, Inc.     

Gene patents and capital investment

Will the US Supreme Court''s ruling that genes can no longer be patented in the USA boost venture capital investment into biotech and medical startup companies?Three years ago, Noubar Afeyan, managing partner and CEO of Flagship Ventures, an early-stage venture capital firm in Cambridge, Massachusetts, USA, was working with a biotech start-up company developing techniques for BRCA gene testing for breast cancer risk that avoided the patents held by Myriad Genetics, a molecular diagnostics company in Salt Lake City (Utah, USA) and the only operator in the field. However, despite the promise of the start-up''s techniques, investors were put off by Myriad''s extensive patent portfolio and fiercely defensive tactics: “A lot of investors were simply not willing to take that chance, even though our technology was superior in many ways and patentably different,” Afeyan said. The effort to launch the start-up ultimately failed.…it is also not clear how the Supreme Court''s ruling will affect the […] industry at large, now that one of the most contested patents for a human gene has been ruled invalidAfeyan believes the prospects for such start-ups improved on the morning of 13 June 2013 when the US Supreme Court ruled in an unanimous vote that Myriad''s fundamental patents on the BRCA1 and BRCA2 genes themselves are invalid, opening up the field to new competitors. The court''s ruling, however, validated Myriad''s patents for BRCA cDNA and methods-of-use.The court''s decision comes at a time when venture capital investment into the life sciences is projected to decline in the years ahead. Some believe that the court''s decision sets a precedent and could provide a boost for products, diagnostics and other tests under development that would have been legally difficult in the light of existing patents on human and other DNA sequences.The US Patent Office issued the original patents for the BRCA 1 and BRCA2 genes in 1997 and 1998 for the US National Institute of Environmental Health Services, the University of Utah and Myriad Genetics. One year earlier, Myriad had launched its first diagnostic test for breast cancer risk based on the two genes and has since aggressively defended it against both private and public competitors in court. Many universities and hospitals were originally offering the test for a lower cost, but Myriad forced them to stop and eventually monopolized BRCA-based diagnostics for breast cancer risk in the USA and several other countries.“Myriad did not create anything,” Justice Clarence Thomas wrote in the Supreme Court''s decision. “To be sure, it found an important and useful gene, but separating that gene from its surrounding genetic material is not an act of invention.” Even so, the court did uphold Myriad''s patents on the methodology of its test. Ron Rogers, a spokesman for the biotech firm, said the Supreme Court had “affirmed the patent eligibility of synthetic DNA and underscored the importance and applicability of method-of-use patents for gene-based diagnostic tests. Before the Supreme Court case we had 24 patents and 520 claims. After the Supreme Court decision, we still have 24 patents. […] [T]he number of our patent claims was reduced to 515. In the Supreme Court case itself, only nine of our 520 patent claims were at issue. Of the nine, the Supreme Court ruled that five were not patent-eligible and they ruled that four were patent-eligible. We still have strong intellectual property protection surrounding our BRCA test and the Supreme Court''s decision doesn''t change that.”Within hours of the ruling, capitalism kicked into high gear. Two companies, Ambry Genetics in Alieso Viejo, California, and Gene by Gene Ltd in Houston, Texas, USA, announced that they were launching tests for the BRCA1 and BRCA2 genes for less than the US$3,100 Myriad has been charging privately insured patients and US$2,795 for patients covered by Medicare—the government health plan for the elderly and disabled. Several other companies and universities also announced they would be offering BRCA testing.Entrepreneur Bennett Greenspan, a managing partner of Gene by Gene, explained that his company had been poised to offer BRCA testing if the Supreme Court ruled against Myriad. He said, “We had written a press release with our PR firm a month before the release of the Supreme Court with the intention that if the Supreme Court overruled the patent or invalidated the patent that we would launch right away and if they didn''t, we would just tear up the press release.” His company had previously offered BRCA gene testing in Israel based on guidelines from the European Union.Myriad Genetics has not given up defending its patents, however. On 9 and 10 July 2013, it slapped Ambry and Gene by Gene with lawsuits in the US District Court in Salt Lake City for allegedly infringing on patents covering synthetic DNA and methods-of-use related to the BRCA1 and BRCA2 genes. Rogers commented that the testing processes used by the firms “infringes 10 patents covering synthetic primers, probes and arrays, as well as methods of testing, related to the BRCA1 and BRCA2 genes.”On 6 August 2013, Ambry countersued Myriad, arguing that the company “continues a practice of using overreaching practices to wrongfully monopolize the diagnostic testing of humans'' BRCA1 and BRCA2 genes in the United States and to attempt to injure any competitor […] Due to Myriad''s anticompetitive conduct, customers must pay significantly higher prices for Myriad''s products in the relevant market, often nearly twice as high as the price of Ambry''s products and those of other competitors” [1].Just as the courts will have to clarify whether the competitors in this case infringe on Myriad''s patents, it is also not clear how the Supreme Court''s ruling will affect the biotech and diagnostics industry at large, now that one of the most contested patents for a human gene has been ruled invalid. In recent years, venture capital investment into the life sciences has been in decline. The National Venture Capital Association and the Medical Innovation & Competitiveness Coalition reported from a survey that, “An estimated funding loss of half a billion dollars over the next three years will cost America jobs at a time when we desperately need employment growth” [2]. The survey of 156 venture capital firms found that 39% of respondents said they had reduced investment in the life sciences during the previous three years, and the same proportion intended to do so in the next three years. “[US Food and Drug Administration] FDA regulatory challenges were identified as having the highest impact on these investment decisions,” the report states, adding that many investors intended to shift their focus from the US towards Europe and the Asia/Pacific region.Another report from the same groups explains how public policy involving the FDA and other players in “the medical innovation ecosystem”—including the US patent system, public agencies, tax policy, securities regulation, immigration laws and private groups such as insurers—affect the decisions of investors to commit to funding medical innovation [3].Some investors think that the court decision about the patentability of human DNA will increase confidence and help to attract investors back to the life sciencesSome investors think that the court decision about the patentability of human DNA will increase confidence and help to attract investors back to the life sciences. “The clarity is helpful because for the longest time people didn''t do things because of ambiguity about whether those patents would be enforceable,” Afeyan said. “It''s one thing to not do something because of a patent, it''s another to not do something because you know that they have patents but you''re not sure what it''s going to stop you from doing because it hasn''t been really fully fleshed out. Now I think it is reasonably well fleshed out and I think you will see more innovation in the space.”Others also appreciate the clarification from the Supreme Court about what is a patentable invention in regard to human genes and DNA. “The Myriad decision was a very solid reading of the underlying purpose of our patent law, which is to reward novel invention,” commented Patrick Chung, a partner with New Enterprise Associates, a venture capital firm in Menlo Park, California, which invested in 23andMe, a personal genomics company based in Mountain View (California, USA), and who serves on the 23andMe board.But not everyone agrees that the Supreme Court''s decision has provided clarity. “You could spin it and say that it was beneficial to create some certainty, but at the end of the day, what the Court did was reduce the scope of what you''re allowed to get patent claims on,” said Michael Schuster, a patent lawyer and Intellectual Property Partner and Co-Chair of the Life Sciences Group at Fenwick & West LLP in San Francisco, California, USA. “It''s going to be a continuing dance between companies, smart patent lawyers, and the courts to try to minimize the impact of this decision.”Kevin Noonan, a molecular biologist and patent lawyer with McDonnell Boehnen Hulbert & Berghoff LLP in Chicago, Illinois, USA, commented that he does not expect the Supreme Court decision will have much of an impact on venture investments or anything else. “This case comes at a time fortunately when biotechnology is mature enough so that the more pernicious effects of the decision are not going to be quite as harmful as they would if this had happened ten, 15 or 20 years ago,” he said. “We''re now in the ‘post-genomic'' era; since the late ‘90s and turn of the century, the genomic and genetic data from the Human Genome Project have been on publicly available databases. As a consequence, if a company didn''t apply for a patent before the gene was disclosed publicly, it certainly is not able to apply for a patent now. The days of obtaining these sequences and trying to patent them are behind us.”Noonan also noted that the Myriad Genetics patents were due to expire in 2014–2015 anyway. “Patents are meaningless if you can''t enforce them. And when they expire, you can no longer enforce them. So it really isn''t an impediment to genetic testing now,” he explained. “What the case illustrates is a disconnect between scientists and lawyers. That''s an old battle.”George Church, professor of genetics at Harvard Medical School (Boston, Massachusetts, USA) and Director of the Personal Genome Project, maintains that the Supreme Court decision will have minimal influence on the involvement of venture capitalists in biotech. “I think it''s a non-issue. It''s basically addressing something that was already dead. That particular method of patenting or trying to patent components of nature without modification was never really a viable strategy and in a particular case of genes, most of the patents in the realm of bio-technology have added value to genes and that''s what they depend on to protect their patent portfolio—not the concept of the gene itself,” he said. “I don''t know of any investor who is freaked out by this at all. Presumably there are some, because the stock oscillates. But you can get stock to oscillate with all kinds of nonsense. But I think the sober, long-term investors who create companies that keep innovating are not impacted.”Church suggests that the biggest concern for Myriad now is whole-gene sequencing, rather than the Supreme Court''s decision. “Myriad should be worrying about the new technology, and I''m sure they''ve already considered this. The new technology allows you to sequence hundreds of genes or the whole genome for basically the price they''ve been charging all along for two genes. And from what I understand, they are expanding their collection to many genes, taking advantage of next generation sequencing as other companies have already,” he said.Whatever its consequences in the US, the Supreme Court''s decision will have little impact on other parts of the world, notably Europe, where Myriad also holds patents on the BRCA genes in several countries. Gert Matthijs, Head of the Laboratory for Molecular Diagnostics at the Centre for Human Genetics in Leuven, Belgium, says that even though the US Supreme Court has invalidated the principle of patenting genes in America, the concept remains in Europe and is supported by the European Parliament and the European Patent Convention. “Legally, nothing has changed in Europe,” he commented. “But there is some authority from the US Supreme Court even if it''s not legal authority in Europe. Much of what has been used as arguments in the Supreme Court discussions has been written down by the genetics community in Europe back in 2008 in the recommendations on behalf of the European Society for Human Genetics. The Supreme Court decision is something that most of us in Europe would agree upon only because people have been pushing towards protecting the biotech industry that the pendulum was so way out in Europe.”Benjamin Jackson, Senior Director of legal affairs at Myriad Genetics, commented that Myriad holds several patents in Europe that are not likely to be affected by the Supreme Court''s ruling. “The patent situation both generally and for Myriad is a lot clearer in Europe. The European Union Biotech Directive very clearly says that isolated DNA is patentable even if it shares the same sequence as natural DNA,” he said. “Right now, it''s pretty uncontroversial, or at least it''s well settled law basically in Europe that isolated DNA is patentable.” However, while the Directive states that “biological material which is isolated from its natural environment or produced by means of a technical process” might be patentable “even if it previously occurred in nature”, the European Patent Office (EPO) in Munich, Germany, requires that the subject matter is an inventive step and not just an obvious development of existing technology and that the industrial application and usefulness must be disclosed in the application.Myriad has opened a headquarters in Zurich and a lab in Munich during the past year, hoping to make inroads in Europe. In some EU countries, Myriad offers its BRCA test as part of cancer diagnosis. In other countries, BRCA testing is conducted at a fraction of what Myriad charges in the USA, either because institutions ignore the patents that are not enforced in their jurisdictions, or because these countries, such as Belgium, were not included in the patent granted by the European Patent Office. Moreover, in various countries BRCA testing is only available through the healthcare system and only as part of a more extensive diagnosis of cancer risk. In addition, as Matthijs commented, “[t]he healthcare system in Europe is very heterogeneous and that''s also of course a big impediment for a big laboratory to try and conquer Europe because you have to go through different reimbursement policies in different countries and that''s not easy.”Ultimately, it seems the Supreme Court''s decision might turn out to have little impact on biotech firms in either the USA or Europe. Technological advances, in particular new sequencing technologies, might render the issue of patenting individual genes increasingly irrelevant.     

Assessing changes in genomic divergence following a century of human‐mediated secondary contact among wild and captive‐bred ducks

Along with manipulating habitat, the direct release of domesticated individuals into the wild is a practice used worldwide to augment wildlife populations. We test between possible outcomes of human‐mediated secondary contact using genomic techniques at both historical and contemporary timescales for two iconic duck species. First, we sequence several thousand ddRAD‐seq loci for contemporary mallards (Anas platyrhynchos) throughout North America and two domestic mallard types (i.e., known game‐farm mallards and feral Khaki Campbell's). We show that North American mallards may well be becoming a hybrid swarm due to interbreeding with domesticated game‐farm mallards released for hunting. Next, to attain a historical perspective, we applied a bait‐capture array targeting thousands of loci in century‐old (1842–1915) and contemporary (2009–2010) mallard and American black duck (Anas rubripes) specimens. We conclude that American black ducks and mallards have always been closely related, with a divergence time of ~600,000 years before present, and likely evolved through prolonged isolation followed by limited bouts of gene flow (i.e., secondary contact). They continue to maintain genetic separation, a finding that overturns decades of prior research and speculation suggesting the genetic extinction of the American black duck due to contemporary interbreeding with mallards. Thus, despite having high rates of hybridization, actual gene flow is limited between mallards and American black ducks. Conversely, our historical and contemporary data confirm that the intensive stocking of game‐farm mallards during the last ~100 years has fundamentally changed the genetic integrity of North America's wild mallard population, especially in the east. It thus becomes of great interest to ask whether the iconic North American mallard is declining in the wild due to introgression of maladaptive traits from domesticated forms. Moreover, we hypothesize that differential gene flow from domestic game‐farm mallards into the wild mallard population may explain the overall temporal increase in differentiation between wild black ducks and mallards, as well as the uncoupling of genetic diversity and effective population size estimates across time in our results. Finally, our findings highlight how genomic methods can recover complex population histories by capturing DNA preserved in traditional museum specimens.     

Merriam's Turkey Nest Survival and Factors Affecting Nest Predation by Mammals

Abstract: Nest success is an important parameter affecting population fluctuations of wild turkeys (Meleagris gallopavo). Factors influencing mammalian predation on turkey nests are complicated and not well understood. Therefore, we assessed nest hazard risk by testing competing hypotheses of Merriam's turkey (M. g. merriami) nest survival in a ponderosa pine (Pinus ponderosa) ecosystem during 2001–2003. We collected nesting information on 83 female Merriam's turkeys; annual nest success averaged 50% for adult females (range = 45–59%) and 83% for yearling females (range = 75–100%). Proportional hazard modeling indicated that precipitation increased the hazard of nest mortality. However, estimated hazard of nest predation was lowered when incubating females had greater shrub cover and visual obstruction around nests. Coyotes (Canis latrans) were the primary predator on turkey nests. We hypothesize that precipitation is the best predictor of nest survival for first nests because coyotes use olfaction effectively to find nesting females during wet periods. Temporally, as the nesting season progressed, precipitation declined and vegetation cover increased and coyotes may have more difficulty detecting nests under these conditions later in the nesting period. The interaction of concealment cover with precipitation indicated that nest hazard risk from daily precipitation was reduced with greater shrub cover. Management activities that promote greater shrub cover may partially offset the negative effects of greater precipitation events.     

Absence of Tau triggers age‐dependent sciatic nerve morphofunctional deficits and motor impairment

Dementia is the cardinal feature of Alzheimer's disease (AD), yet the clinical symptoms of this disorder also include a marked loss of motor function. Tau abnormal hyperphosphorylation and malfunction are well‐established key events in AD neuropathology but the impact of the loss of normal Tau function in neuronal degeneration and subsequent behavioral deficits is still debated. While Tau reduction has been increasingly suggested as therapeutic strategy against neurodegeneration, particularly in AD, there is controversial evidence about whether loss of Tau progressively impacts on motor function arguing about damage of CNS motor components. Using a variety of motor‐related tests, we herein provide evidence of an age‐dependent motor impairment in Tau?/? animals that is accompanied by ultrastructural and functional impairments of the efferent fibers that convey motor‐related information. Specifically, we show that the sciatic nerve of old (17–22‐months) Tau?/? mice displays increased degenerating myelinated fibers and diminished conduction properties, as compared to age‐matched wild‐type (Tau+/+) littermates and younger (4–6 months) Tau?/? and Tau+/+ mice. In addition, the sciatic nerves of Tau?/? mice exhibit a progressive hypomyelination (assessed by g‐ratio) specifically affecting large‐diameter, motor‐related axons in old animals. These findings suggest that loss of Tau protein may progressively impact on peripheral motor system.     

Current status and recent trend of the Eurasian Woodcock Scolopax rusticola as a breeding bird in Britain

Capsule The breeding Woodcock population in Britain in 2013 was estimated at 55?241 males (95% CL: 41?806–69?004), suggesting a large-scale decline that is supported by 2 additional sources of data.

Aims To provide an updated estimate of the size of Britain's breeding Woodcock population, measure recent trends and identify spatial patterns of change.

Methods Displaying male Woodcock were surveyed at a stratified sample of 834 randomly selected sites. Population estimates were compared with a baseline survey conducted in 2003 and the trend with data from annual Woodcock counts (2003–13) and Bird Atlas 2007–11.

Results Woodcock were estimated to be present at 22% of 1?×?1?km squares containing ≥10?ha of woodland, compared to 35% in 2003. The British population estimate fell by 29% between 2003 and 2013. The Atlas suggests that presence at the 10?×?10?km scale has declined by 56% between 1970 and 2010. Both data sources suggest regional variation in the rate of decline, with losses greatest in the West and South.

Conclusion The Woodcock's population size and breeding range appear to be declining severely across Britain. Regional variation in the rate of decline might be explained by the distribution of large continuous woodlands.     

Successful field capture techniques for free‐ranging argali sheep (Ovis ammon) in Mongolia

Argali sheep (Ovis ammon) are the world's largest wild sheep and are threatened throughout their range in Mongolia. Little is known about the ecology of this highly cursorial species. This project was initiated to develop safe capture techniques in order to learn more about the ecology of argali in the Ikh Nartiin Chuluun Nature Reserve in southeastern Mongolia by using radiotelemetry. To our knowledge no one had ever successfully live‐caught a free‐ranging argali. We developed three techniques for capturing argali. From 2003 to 2007 we hand captured 65 argali lambs, losing one (our first capture) to maternal neglect because we stayed too long in the area and a second that was euthanized after being accidentally injured by a horse. Between 2000 and 2003 we captured six argali by darting, losing one ewe to an abdominal infection after a misplaced dart. Finally, between 2002 and 2007 we captured 32 argali by drive‐netting. We lost one ewe to over‐exertion after a long drive. The remaining 31 animals captured by drive‐netting did not appear to suffer any immediate effects (still alive in 30 days). This report will discuss the strengths and weaknesses for each of these capture techniques. Zoo Biol 27:137–144, 2008. © 2008 Wiley‐Liss, Inc.     

Genetic diversity in captive and wild Matschie's tree kangaroo (Dendrolagus matschiei) from Huon Peninsula,Papua New Guinea,based on mtDNA control region sequences

The Association of Zoos and Aquariums (AZA) Matschie's tree kangaroo (Dendrolagus matschiei) population is at a critical point for assessing long-term viability. This population, established from 19 genetically uncharacterized D. matschiei, has endured a founder effect because only four individuals contributed the majority of offspring. The highly variable mitochondrial DNA (mtDNA) control region was sequenced for five of the female-founders by examining extant representatives of their maternal lineage and compared with wild (n=13) and captive (n=18) D. matschiei from Papua New Guinea (PNG). AZA female-founder D. matschiei control region haplotype diversity was low, compared with captive D. matschiei held in PNG. AZA D. matschiei have only two control region haplotypes because four out of five AZA female-founder D. matschiei had an identical sequence. Both AZA haplotypes were identified among the 17 wild and captive D. matschiei haplotypes from PNG. Genomic DNA extracted from wild D. matschiei fecal samples was a reliable source of mtDNA that could be used for a larger scale study. We recommend a nuclear DNA genetic analysis to more fully characterize AZA D. matschiei genetic diversity and to assist their Species Survival Plan^®. An improved understanding of D. matschiei genetics will contribute substantially to the conservation of these unique animals both in captivity and the wild. Zoo Biol 28:183–196, 2009. © 2008 Wiley-Liss, Inc.     

Rating vs. coding in animal personality research

Animal personality research has become increasingly popular over the past few decades. The two main methods used to examine individual differences in animals are rating and coding. The rating method involves human scoring of an animal's behavioral tendencies along various behavioral dimensions, such ratings are typically based on the human rater's experience with the animal. The coding method also requires humans to score an animal's behavior, but differs in that the scoring is based on the animal's immediate behavior in a specific context. This brief report describes the use of both the rating and coding methods to examine personality within a group of 10 Garnett's bushbabies (Otolemur garnettii). The results indicated that individual personalities do exist in bushbabies, but also suggested that the rating method is heavily influenced by the rater's experience with an animal. Consequently, it is important that the nature of the rater's interactions with the target animals be considered when using the rating method to assess animal personality. Zoo Biol 29:509–516, 2010. © 2009 Wiley‐Liss, Inc.     

Diet composition and selection of Père David's deer in Hubei Shishou Milu National Nature Reserve,China

Hubei Shishou Milu National Nature Reserve is an ideal place to restore the wild population of Père David's deer (Elaphurus davidianus). Understanding foraging ecology and diet composition is essential for assessing population development or establishing long-term effective conservation measures for endangered species. However, little is known about the diet composition of Père David's deer and its diet selection mechanism. In this study, we used stable isotope technology to investigate the diet composition of Père David's deer according to various tissues (i.e., fur, muscle, liver, heart, and feces) and seasons, and evaluated the correlation between the nutrient composition of plants and diet composition. Bayesian isotope analysis showed that the autumn and winter diet estimated by fur and fecal samples indicated a diet dominated by C₃ grasses (42.7%–57.2%, mean), while the summer diet estimated by muscle and liver samples was dominated by C₃ forbs (30.9%–41.6%, mean). The Pearson correlation test indicated that the contribution of winter diet composition reflected by fur and fecal samples was associated with correlations with crude protein (r = .666, p < .01) and soluble sugars (r = .695, p < .01). The results indicated that crude protein and soluble sugars were important factors influencing the winter diet selection of Père David's deer. In the context of the current reintroduction facing many challenges, such as habitat fragmentation, wetland degradation, and human disturbance, comprehensively evaluating the diet selection mechanism of Père David's deer under different resource specificities and temporal changes should be considered in the future.     

Teeth emergence in wild olive baboons in Kenya and formulation of a dental schedule for aging wild baboon populations

Teeth emergence schedules are presented from analysis of 95 wild olive baboons Papio anubis (age range 2–120 months) and compared to recently published results for wild and captive yellow baboons (P. cynocephalus; Phillips-Conroy and Jolly: American Journal of Primatology 15:17–29, 1988). Age at emergence of M1 (20.5 months males, 19.5 months females), I1 (32.5 and 33.5 months) and I2 (40.0 and 39 months) of olive baboons was earlier than in the wild yellow baboons and similar to captive yellow baboons. However, the later emerging teeth were delayed considerably relative to the captive animals and were similar in age of emergence to those of wild yellow baboons. Considerable variation in age of emergence occurred in the later emerging teeth especially among males. Regression analysis of dental scores with age demonstrated differences between olive baboons and captive yellow baboons but not between olive baboons and wild yellow baboons. Combined data on dental scores for wild yellow, olive, and hamadryas baboons provide schedules of AGE (months) = {SCORE – 11.79} ÷ 0.4405 and AGE (months) = {SCORE – 11.24} ÷ 0.4797 for males and females, respectively, which may be used for aging wild baboons. Full permanent dentition in wild baboons is predicted to occur over 1 year later than in captive animals.